Cavernous hemangioma of the liver: factors affecting disease progression in general hepatology practice

Arash Etemadi1, Asieh Golozar, Akhgar Ghassabian

  • 1Digestive Disease Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Insights

Hepatic hemangiomas, especially single large ones, may cause persistent pain and grow over time. Accompanying gastrointestinal issues often contribute to symptoms in patients with liver hemangiomas.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Radiology

Background:

  • Hepatic hemangiomas are typically managed conservatively, but factors influencing their progression remain unclear.
  • Understanding disease characteristics is crucial for effective patient management.

Purpose of the Study:

  • To investigate the clinical features of hepatic cavernous hemangiomas.
  • To identify factors influencing the progression of liver hemangiomas.

Main Methods:

  • Retrospective review of 198 patients with liver hemangioma from a hepatology clinic (1997-2007).
  • Follow-up data for 129 patients over 3.2 ± 2.5 years, including 80 with repeated sonographies.

Main Results:

  • Female predominance (66.2%); 18.2% had giant hemangiomas.
  • Abdominal pain was common, associated with irritable bowel syndrome and other GI diseases, not hemangioma characteristics.
  • Single giant lesions predicted persistent pain (OR=11.1).
  • 35% of lesions increased in size, associated with single lesions (P=0.04).

Conclusions:

  • Symptoms in hepatic hemangioma patients are often linked to concurrent gastrointestinal diseases.
  • Single giant hepatic hemangiomas are prone to persistent pain and size increase.
  • This highlights the importance of considering associated GI conditions and lesion characteristics in management.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...